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Extracellular matrix moleculea b s t r a c t
Biomarkers are extremely important in the case of multisystemic diseases, such as lysosomal stor-
age disorders (LSDs), which are often difﬁcult to assess in clinical practice. Several studies demon-
strated signiﬁcant alterations in the expression of extracellular matrix (ECM) components in LSD
patients, raising important questions in relation to their possible involvement in disease pathogen-
esis and providing evidence for their possible utility as disease biomarkers. This article provides an
overview of the possible pathogenic correlations between LSDs and ECM. Data regarding the expres-
sion of these molecules are discussed. Finally, the possible implication of ECM components as ther-
apeutic targets in this group of diseases along with the impact of the differential expression of these
components in current LSD treatment will be critically addressed.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The lysosome represents an important organelle involved in
multiple cell processes, usually through dynamic interactions with
other cellular compartments. Thus, it is not surprising that deﬁ-
ciencies of speciﬁc proteins which are integral to lysosomal func-
tion give birth to a broad spectrum of almost 70 genetically
distinct metabolic conditions, known as Lysosomal Storage Disor-
ders (LSDs) [1]. Although they are individually rare, LSDs have a
combined frequency of almost 1 incident in every 7500 live births
[2] and may present with a wide range of clinical manifestations
and a variable degree of involvement regarding different organs
and systems.
The multisystemic nature of LSDs, as well as the irreversibility
of many features which characterize them, often render the assess-
ment of patients with the use of common clinical, radiological and
laboratory tests, difﬁcult in practice. Thus – and in accordance withnumerous other pathologic conditions – there is great ongoing ef-
fort for the discovery of speciﬁc chemical analytes, also known as
biomarkers (BMs), indicative of a particular biological process.
The advent of enzyme replacement therapy (ERT) for Gaucher dis-
ease, which gave rise to the current revolution in the search of no-
vel treatment modalities, in combination with the great potential
in diagnosis unraveled by the application of new molecular tech-
niques, highlighted even more the need for efﬁcacious BMs. The
latter are extremely important in monitoring both disease mani-
festations and efﬁcacy of any treatment applied, while also they
are expected to play a signiﬁcant role in orphan drug development
[3].
In the case of LSDs 3 categories of BMs are currently distin-
guished [3,4]. The ﬁrst category includes molecules that accumu-
late directly as a result of the genetic defect, which leads to the
enzymatic deﬁciency. The second category comprises molecules
whose expression is modiﬁed in affected tissues as a result of the
primary pathological storage. A third category of less speciﬁc
markers includes proteins generally released in the circulation
due to the lysosomal dysfunction, which could potentially be more
representative of total body burden rather than reﬂect a particular
organ or system involvement [5]. All these molecules should have
certain speciﬁc characteristics in order to ensure that their applica-
tion is safe and reliable for the assessment of patients in the clinical
setting [4]. Some of the features of an ideal BM include the simple
and rapid assessment in easily accessible tissues and body ﬂuids,
the ideal reﬂection of total body burden of the disease, the narrow
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general population and the absence of overlap between the quan-
tity of the analyte in naive patients and healthy subjects [4]. Apart
from the identiﬁcation and common employment of plasma chitot-
riosidase as a ﬁrst screen in Gaucher disease [6], there are currently
very few BMs in LSDs, of which even fewer are engaged in clinical
use [7–16].
The extracellular matrix (ECM) represents an intricate network
of macromolecules whose components represent research targets
concerning BM discovery in numerous pathologic conditions.
Extensive research over the last 30 years has led to a great appre-
ciation of the widespread functional importance and dynamic roles
of the ECM in diverse cellular processes. Following a brief summary
about the various components of the ECM and their functions, this
article provides an overview of the possible pathogenic correla-
tions between LSDs and ECM. Data regarding the expression of
these molecules, in both animal models and human subjects, in
mucopolysaccharidoses (MPS) and other LSDs will be discussed.
Along with the possible implication of these molecules as thera-
peutic targets in various LSDs, existing literature, regarding the im-
pact of the differential expression of the ECM components in
current treatment applied in this group of diseases, will be also
critically addressed.
2. The ECM: molecules & functions
The ECM represents an interconnected meshwork of macromol-
ecules, a physical scaffold for cell and tissue organization, as well
as a microenvironment providing contextual information that
inﬂuences processes of any cell type [17]. Through its function, it
regulates growth factors, chemokine and cytokine availability, con-
tributes to tissue homeostasis maintenance and inﬂuences cell
proliferation, differentiation, motility and survival [18–22]. The
ECM is composed of several distinct families of molecules, present-
ing dynamic interactions with each other and with diverse types of
cells. As it has been widely acknowledged, alterations of its compo-
sition trigger the manifestation of numerous pathologic conditions
[17,23,24]. Components of the ECM include diverse ﬁbrous ele-
ments, different classes of proteoglycans (PGs), hyaluronic acid
(HA) and ﬁnally a great number of proteolytic enzymes which
are responsible for the dissolution of the ECM.
The ﬁbrous elements of the ECM represent a vast portion of its
macromolecules in most tissues and are divided in collagens and a
diverse array of non-collageneous proteins. Collagens are distin-
guished in 28 different types among which type I, III, IV, and VI
are the most prominent [25]. Although they are often thought as
inert structures that provide tensile strength, they have been found
to hold both pro- and anti-inﬂammatory properties [26–28]. It was
demonstrated that they regulate cell adhesion and chemotaxis,
while they also promote direct tissue development [22]. Apart
from collagens, numerous glycoproteins, like laminins, ﬁbronectin,
thrombospondins and tenascins, represent ﬁbrous elements of the
ECM, too [18,19]. They are known for their function as growth fac-
tor repositories and, hence, are implicated in cell adhesion and sig-
naling, as well as ECM-cell interactions [18,19].
Glycosaminoglycans (GAGs) represent the most abundant poly-
saccharides of the ECM and, at the same time, the primary storage
material in MPS. They are linear polymers consisting of repeating
disaccharide units and, according to their biochemical structure,
they are divided in HA, chondroitin sulfate, dermatan sulfate, ker-
atan sulfate and ﬁnally heparin and heparan sulfate. With the
exception of HA, all the other GAGs are covalently attached to pro-
tein structures in order to form PGs [29]. There are more than 30
different PG molecules which can be divided in several distinct
families [19,29,30]. PGs are found predominantly in the ECM orassociated with the cell surface of most eukaryotic cells where they
bind to other matrix- and cell-associated components and are
implicated in numerous cell processes. Cell proliferation, migration
and adhesion, tissue morphogenesis and development, inﬂamma-
tory response reaction, growth factor availability and water and
calcium homeostasis are only some among the numerous path-
ways and cell functions where these molecules are involved
[19,29–32].
HA is the only member of the GAG family found in the ECM
without a protein core and is detected in tissues as high or low
molecular mass macromolecule. It is synthesized by numerous cell
types and is abundant in many tissues of the human body [33].
Thus, it is not surprising that the concentration of HA is altered
in a plethora of pathologic conditions affecting diverse organs such
as the brain, bones, liver, kidneys, heart and lungs [33]. Its metab-
olism is regulated by three hyaluronan synthase genes [34] and the
various isoforms of degrading hyaluronidases [35]. In order to ex-
ert its functions, HA is recognized by cell surface receptors, notably
CD44 and receptor for HA mediated motility (RHAMM) [36,37].
Interaction of this highly metabolically active molecule with its
receptors has a triggering effect on several intracellular signaling
pathways, which in turn regulate cell proliferation, migration and
differentiation [37,38]. It is also known that HA acts as an immune
regulator and activates a wide range of inﬂammatory cells [33,38].
The ECM represents a constantly changing environment with
macromolecules whose expression is regulated driven by two
opposing forces: synthesis and deposition on one hand, and prote-
olytic breakdown on the other. There are numerous families of pro-
teolytic enzymes involved in the dissolution of the ECM [39,40].
Most prominent among them are matrix metalloproteinases
(MMPs), a growing family of 24 zinc-dependent endopeptidases
classiﬁed according to domain structure into collagenases, gelatin-
ases, stromelysins, matrilysines, membrane-type and others [41].
They represent key enzymes involved in tissue remodeling [42]
and have been implicated in diverse normal and pathological pro-
cesses, usually related to inﬂammation and cell apoptosis [43–45].
All MMPs are secreted as inert zymogens and require a proteolytic
cleavage of a propeptide in order to be activated, whereas their
transcription, translation and pro-enzyme activity are regulated
by a wide spectrum of molecules, such as growth factors, cytokines
and tissue inhibitors of metalloproteinases (TIMPs) [46,47]. TIMPs
represent a family of 4 distinct members that bind to MMPs in a
1:1 stoichiometric ratio in order to block MMP activity [46]. They
have different afﬁnity patterns with various MMPs and their
expression is regulated by cytokines and growth factors [47]. Dur-
ing the last years they have been found to exert additional proper-
ties, being implicated not only in the blockage but also in the
activation of MMPs [48].
3. Pathogenic correlations between LSDs & ECM molecules
Unraveling the affected cellular pathways that cause the mani-
festation of each LSD represents the ﬁrst and probably the most
important step for the discovery of speciﬁc disease BMs. Yet, this
relationship is rather bidirectional: the study of molecules, which
are differentially expressed in response to a metabolic defect, has
been extremely fruitful in providing mechanistic insight into the
molecular pathogenesis of this group of diseases. In addition, the
ﬁnding that some chemical analytes, such as chitotriosidase, were
found to be elevated in a number of LSDs, has enhanced the notion
that although each disorder is best considered as a singularity,
most LSDs share common aetiopathological mechanisms [6]. The
initial hypothesis postulated that the primary enzyme deﬁciency
is followed by the intralysosomal accumulation of a single major
substrate normally degraded by that enzyme, causing lysosomal
Table 1
Summary of the main ﬁndings of various studies concerning the expression of ECM molecules in LSDs.
ECM molecule Disease Subject Findings Ref. no.
Fibrous elements MPS IVA Human Increased collagen ﬁbril diameter of articular cartilage [92,93]
MPS IVA Human Increased collagen type I expression [93]
MPS IVA Human Decreased collagen type II expression in chondrocytes [94]
MPS VI Animal Decreased collagen IIA1 and X in articular chondrocytes [95]
MPS I Human Increased ﬁbril diameter of the cornea [96–99]
MPS IIIA, IIIB and VI Human Increased ﬁbril diameter of the cornea [96]
MPS IVA Human Increased ﬁbril diameter of the cornea [100]
MPS VII Human Decreased ﬁbril diameter of the cornea [76]
MPS IIB Human Unaltered collagen expression in ﬁbroblasts [102]
MPS IIIB Human Decreased ﬁbronectin expression in ﬁbroblasts and increased neural stem cells [102]
MPS IIB Human Decreased elastin expression in ﬁbroblasts [102]
MPS I Animal Increased elastin fragmentation in ascending aorta [103–
104]
MPS VII Animal Increased elastin fragmentation in aorta [104]
Fabry Human Increased collagen type IV and ﬁbronectin expression in podocytes [105]
GM1 Gangliosidosis Animal Decreased collagen type II expression in chondrocytes [106]
I-Cell Human Decreased collagen ﬁbril diameter in chondrocytes [107]
Sialidosis Animal Increased collagen and a2-laminin expression in skeletal muscle [89]
Krabbe Animal Increased laminin and ﬁbronectin production from activated scwann cells [109]
Aspartyglucosaminuria Human Abnormal variation in collagen ﬁbril diameter and reduction in their production [110]
Aspartyglucosaminuria Human Decreased collagen type I and III expression in ﬁbroblast cell cultures [111]
Aspartyglucosaminuria Human Variation in collagen ﬁbril diameter in gingival tissue [112]
Chediak-Higashi Animal Decreased collagen production in the oral mucosa [113]
Pompe Human Increased collagen biosynthesis in the gingival tissue [114]
Proteoglycans Various MPS types Human No alteration in proteoglycan turnover in ﬁbroblast cell cultures [115]
MPS IV Human Alteration in the arrangement and increased production of PGs in articular cartilage [92–93]
MPS IV Human Decreased aggrecan expression in articular cartilage [93]
MPS IV Animal Up-regulation in aggrecan expression in chondrocytes [94]
MPS IX Animal Decreased expression of proteoglycans in articular cartilage [77]
MPS IIIA and B Animal Increased glypican 1 and 5 expression in the medial entorhinal cortex [116]
MPS I Human Elongation of proteoglycan ﬁlaments with alterations in their architecture in the cornea [97–98]
MPS IVA Human Elongation of proteoglycan ﬁlaments with alterations in their architecture in the cornea [100]
MPS VII Human Elongation of proteoglycan ﬁlaments with alterations in their architecture in the cornea [76]
MPS VI Human Increased amounts of proteoglycans in the cornea [117]
MPS VII Animal Increased amounts of proteoglycans in the interphotoreceptor matrix [118]
Niemann-Pick C Animal Decreased heparan sulfate proteoglycan degradation in ﬁbroblasts [119]
Neuronal
lipofuscinoses
Human Increased versican expression in ﬁbroblasts [120]
Aspartyglucosaminuria Human Alteration in the epimerization of proteoglycans [110]
Aspartyglucosaminuria Human Decreased biglycan and increased decorin production [111]
Mucolipidosis Human Alteration in proteoglycan expression in cartilage [107]
I-Cell Human Alteration in proteoglycan expression in cartilage [121]
GM1 gangliosidosis Animal Decreased proteoglycan expression in chondrocytes [106]
Hyaluronic acid MPS IX Human Increased concentration in serum hyaluronic acid [122]
MPS IX Animal No alteration in circulating levels of hyaluronic acid [77]
Unknown MPS type? Animal Increased circulating levels of hyaluronic acid [124]
MPS I Human Abnormal hyaluronic acid metabolism with increased synthesis in skin ﬁbroblasts [125]
MPS IIIA Human Increased serum levels of hyaluronic acid with decreased hyaluronidase I activity [126]
MPS IV Human No alteration in hyaluronidase I enzyme activity [126]
MPS VI Human Increased hyaluronic acid concentration in dentigerous cysts [127]
MPS II Human Increased hyaluronic acid content in the adenoids [128]
Mucolipidosis Human Contradictory results in relation to the production of hyaluronic acid by ﬁbroblasts [129–
130]
I-Cell disease Human Increased circulating levels of hyaluronic acid [126]
GM1 gangliosidosis Human No alteration in the enzyme activity of hyaluronic acid degrading enzymes [126]
Matrix
metalloproteinases
MPS I Animal Increased expression and enzyme activity of MMP-12 in aorta [103–
104]
MPS VI and VII Animal Increased expression of MMP-1 and MMP-13 in synovial membranes [131]
MPS VI and VII Animal Increased expression and activity of MMP-2 and MMP-9 in synovial membranes [132]
MPS VII Animal Increased expression and enzyme activity of MMP-12 in aorta [104]
MPS VII Animal Increased expression of MMP-3 in growth plates [133]
MPS VII Animal Increased expression of MMP-2 and MMP-9 in cerebral tissues [134]
MPS VI Human Decreased expression of MMP-9 in white blood cells [135]
MPS IIIB Human Decreased expression of MMP-1 in human pluripotent stem cells [102]
MPS I, III and VI Human Altered expression and enzyme activity of MMP-2 and MMP-9 in serum [136]
Neuronal
lipofuscinoses
Animal Increased expression of MMP-2, MMP-3 and MMP-9 in cerebral tissues [140]
Niemann-Pick A and B Animal Increased expression of MMP-12 in the lungs [10]
Fabry disease Human Increased circulating levels of MMP-9 [141]
Sialidosis Animal Increased expression and enzyme activity of MMP-2 and MMP-9 in muscles [89]
Chediak-Higashi Animal Increased enzyme activity of collagenases and gelatinases in the oral mucosa [142]
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day it is widely accepted that this pathogenic concept is relatively
simplistic and rather misleading. Since lysosomes do not represent
end-organelles but rather a component of a highly complex regu-
latory system [49], it is nowadays recognized that LSDs result from
perturbation of various cellular mechanisms. For example a block
in autophagy represents an almost universal aetiopathogenetic
pathway affected in many LSDs [50–55]. Other cellular pathways
affected in several disorders of this group include biochemical in-
jury due to toxic metabolites, derangements in calcium/iron
homeostasis, abnormalities in endoplasmic reticulum stress re-
sponses and immune-inﬂammatory processes [1,56]. Since abnor-
mal autophagy, inﬂammation and apoptosis represent cellular
processes dependent on lysosomal storage [57] and upon each
other [58,59] the molecules involved in all these distinct pathways
could potentially represent BMs for LSDs. Knowing that many of
the ECM components play signiﬁcant roles in the above mentioned
cellular processes, a search for an LSD BM among this intricate net-
work of macromolecules could be easily justiﬁed.
In addition, in the case of LSDs with neurological involvement,
the setting in the discovery of analytes speciﬁcally related to cen-
tral nervous system (CNS) is even more obscure. These disorders
often require more imaginative approaches and represent an area
of intense investigation in BM discovery, since there are very few
available analytical tools which could potentially demonstrate
CNS involvement [60–62]. The composition and spatial orientation
of ECM varies signiﬁcantly, both quantitatively and qualitatively,
from organ to organ and is carefully regulated. Concerning the
CNS, the extracellular space represents a developmentally decreas-
ing compartment with a quite unique composition, mainly based
on HA and PGs [63]. Through its functions, it regulates various as-
pects of pre- and postsynaptic differentiation, synaptic maturation
and plasticity and neuronal development, migration and pattern-
ing [64–67]. It is nowadays acknowledged that there are major
changes in the expression of numerous ECM molecules in a great
number of diseases. The latter mainly affect the adult brain, such
as Alzheimer disease, Parkinson’s disease, and multiple sclerosis
[68–72]. Nevertheless, the differential expression of ECM mole-
cules in the young brain of LSD patients would not be of great sur-
prise, based on the fact that the pathogenic models explaining the
brain pathology in both neuro-LSDs and adult CNS diseases share
common features [73], with neuro-degeneration and neuro-
inﬂammation representing the hallmark for both groups of dis-
eases [74]. Thus, all the above mentioned molecules could poten-
tially represent surrogate BMs demonstrating CNS involvement.
Although the main cell pathology in LSDs involves the intralys-
osomal accumulation of various molecules, it was recently demon-
strated that substrate deposition is evident in the extralysosomal
milieu and the ECM, as well. Increased levels of the speciﬁc sub-
strate of each disorder have been found in the extralysosomal
and/or ECM in several LSDs, such as in MPS IIIB [75], MPS VII
[76], MPS IX [77], Fabry disease [78–80] and Pompe disease [81].
Partially degraded intracellular substrate breakdown fragments
could potentially be trafﬁcked into the extracellular space in every
LSD, where they could bind to other ECM components and modify
diverse signaling pathways, cell–matrix and cell–cell interactions
[82–83]. In accordance with that, Moro et al. have recently demon-
strated that the reduced iduronate sulfatase activity in a knock-
down animal model of zebraﬁsh results in serious abnormalities
in early vertebrate development [83]. The authors hypothesized
that the alterations found (which characterize human Hunter dis-
ease patients as well) are the result of the interaction between se-
creted PGs or the extracellular portion of membrane-associated
PGs with diverse morphogens which ﬁnally affect transforming
growth factor b signaling [83]. Similar ﬁndings have been reported
in the case of Hurler syndrome: heparin and heparan sulfate canmodulate the biological activity of bone morphogenetic protein-
4, which is an extracellular signaling molecule [84]. In addition,
it was recently shown that the formation of cardiac aneurysms in
Hunter and Maroteaux-Lamy patients results from the extracellu-
lar accumulation of mucopolysaccharides, highlighting the signiﬁ-
cant role of GAGs and PGs in the maintenance of normal cardiac
structure and function [85,86]. Finally, with the use of diffusion
weighted magnetic resonance imaging, Moore et al. demonstrated
that Fabry disease patients exhibit an elevated CNS average diffu-
sion constant, which is consistent with increased ECMwater, prob-
ably due to increased cerebral blood ﬂow [87]. All the above data
represent the sound proof that the ECM is actually affected in var-
ious LSDs and, thus, the expression of its molecules could be signif-
icantly altered.
Despite all the encouraging results from successful treatment in
some LSDs, there is still poor understanding of the biological func-
tions of lysosomal proteins. Recent studies have demonstrated that
many of these enzymes have biological functions which are related
to the ECM. Bhattacharyya et al., have recently found that the
silencing of arylsulfatase B and galactose-6-sulfatase, the responsi-
ble enzymatic deﬁciencies in Maroteaux-Lamy and Morquio syn-
drome respectively, up-regulates the expression of decorin and
syndecan-1 [88]. Subsequently, the authors hypothesized that
these enzymes play an additional role in cellular metabolism of
GAGs and PGs, beyond their known association with MPS. In addi-
tion, another research group recently demonstrated that neuramin-
idase 1, a lysosomal enzyme whose deﬁciency is the basis for
sialidosis, is also related to the ECM [89]. This group has shown that
neuraminidase 1 is capable of inﬂuencing the behavior of ECMmol-
ecules by altering the sialic acid content of various substrates,
pointing a role of this enzyme in ECM remodeling. This ﬁnding pro-
vided direct evidence for the explanation of several systemic abnor-
malities that characterize this LSD, such as the neuromuscular
symptoms of patients, which could potentially result from altera-
tions in the ECM, causing muscle ﬁber degeneration [89]. In agree-
ment with all previous data, two other lysosomal enzymes, b-
glucuronidase and b-N-acetylglucosaminidase, were demonstrated
to be involved in a new pathway of intermediary metabolism of HA
[90], enhancing the notion that the biological functions of several
lysosomal proteins are connected to the ECM. Finally, a recently
published work provided direct evidence that lysosomal enzymes
are not only related to the extracellular space, but can be them-
selves components of the ECM. Fujita et al. have demonstrated that
arylsulfatase A, the enzyme whose deﬁciency leads to the manifes-
tation of metachromatic leukodystrophy, is capable of stimulating
adhesion of human microvascular endothelial cells in vitro, of
affecting the architecture of the cytoskeleton and the distribution
pattern of the cell adhesion-associated proteins and, ﬁnally, of
modulating cytoskeletal rearrangement [91]. These functions of
arylsulfatase A represent properties attributed to an ECMmolecule.
All the above data represent direct evidence of the pathogenic
correlations between LSDs and ECM molecules. An alteration in
the expression of these components could therefore impact LSD
pathogenesis and ﬁnally be reﬂected in body ﬂuids as a potential
BM.
4. Differential expression of ECM molecules in LSDs
Numerous components of the ECM have been studied in various
tissues in both LSD animal models and human patients. Common
characteristic of all this work is the altered expression of several
studied molecules. The research has been relatively productive
especially in the case of MPS where the primary storage material
is actually a component of the ECM. This review will focus on data
regarding the expression of four different groups of extracellular
space molecules. Research ﬁndings concerning the expression of
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other LSDs, will be critically discussed. The results of the main ﬁnd-
ings of various studies concerning the expression of these groups of
ECM components in LSDs are summarized in Table 1.
4.1. Fibrous elements expression in LSDs
The expression of ﬁbrous elements of the ECM in MPS has been
studied in a wide range of cells and tissues. Since MPS patients ex-
hibit signs of bone and joint involvement it is not surprising that
research has focused on the articular cartilage of such patients.
This tissue was histologically and biologically characterized and
alterations in collagen morphology, especially concerning the
diameter of collagen ﬁbrils, were identiﬁed. This diameter was
demonstrated to be increased in MPS IVA [92,93]. More recent
studies have shown that the expression of ﬁbrous elements is al-
tered at the mRNA level, as well. Concerning MPS IVA, collagen
type I expression was found signiﬁcantly increased, while a de-
crease was evident in type II collagen [93,94]. Regarding MPS VI,
the expression of collagen IIA1 and X was lower in articular chon-
drocytes in relation to control healthy cells, but normalization was
demonstrated following the administration of combination ther-
apy with ERT and an anti-TNF-alpha drug [95]. All those differ-
ences in the expression of collagen ﬁbrils have been
hypothesized as the possible cause of osteoarthritis which occurs
at an early age in some MPS patients [92]. Moreover, alterations
in collagen ﬁbril morphology have been reported in the cornea of
patients with various types of MPS. The average ﬁbril diameter
was increased in MPS I [96–99], IIIA [96], IIIB [96], IV [100] and
VI [96], whereas a decrease was demonstrated in MPS VII [76].
Numerous MPS patients exhibit ocular signs and, although the
mechanism which leads to the dysregulation of the shape of colla-
gen is unknown, it was hypothesized that corneal opacity found in
several types of the disease is partly a consequence of the struc-
tural abnormalities in collagen morphology. Although the research
concerning collageneous elements of the ECM revealed signiﬁcant
alterations in chondrocytes and corneal cells, the expression of var-
ious types of collagen seemed unaltered in MPS ﬁbroblast cultures
[101]. Finally, there are few research ﬁndings concerning the
expression of non-collageneous ﬁbrous elements, such as ﬁbronec-
tin [102], elastin [102–104] and tenascins [102]. Those studies
have also pointed to diverse modiﬁcations of ECM components in
MPS.
Various changes in both the expression and morphology of di-
verse ﬁbrous elements of the ECM have been described in a variety
of inherited LSDs. Those alterations are suggestively reﬂected in
the clinical signs and symptoms of each disease. In accordance
with that, a signiﬁcant increase in the expression of collagen type
IV and ﬁbronectin, both at a protein and mRNA level, was recently
identiﬁed in cultured human podocytes in Fabry disease, following
the exposure to lysoGb3 [105]. Thus, the authors hypothesized that
lysoGb3 promotes glomerular injury through the release of sec-
ondary mediators, such as ECM molecules, leading eventually to
the nephropathy of the disease. Another illustrative example of
the connection between ﬁbrous elements’ alterations and the
symptomatology of a speciﬁc disease is that of GM1 gangliosidosis.
In an effort to create an in vitro model to study cartilage matura-
tion in this group of patients, Aulthouse and Alroy have demon-
strated a decrease in collagen type II expression in deﬁcient
canine chondrocytes, as opposed to normal cells [106]. This dys-
regulation in matrix production could represent a possible theory
for the explanation of skeletal abnormalities, not only in GM1 gan-
gliosidosis but in other LSDs, as well, such as in I-cell disease where
a decrease in collagen ﬁbril diameter was noticed in cultured chon-
drocytes [107]. In addition, it was recently demonstrated that
neuraminidase-1 deﬁcient mice have an abnormal expansion inthe epimysial and perimysial spaces of their skeletal muscles
[89]. This expansion was attributed to an increased synthesis of
ECM molecules, which was in accordance with the signiﬁcantly
up-regulated mRNA levels for various types of collagens and a2-
laminin [89]. In agreement with the fact that the same mice exhib-
ited an alteration in aorta and lung elastic ﬁber deposition [108],
this impaired ECM assembly could potentially provide a patho-
genic theory for the explanation of the multisystemic nature of
sialidosis. Expansion of the ECM due to an up-regulation in the
expression of its various ﬁbrous elements was also demonstrated
in Krabbe’s disease [109]. Kagitani-Shimono et al., have shown that
activated Schwann cells from an animal model of globoid cell leu-
kodystrophy secrete large amounts of various ECM molecules
including laminin and ﬁbronectin [109]. Aspartylglucosaminuria
represents another example of LSD with alterations in the expres-
sion of collagen. An abnormal variation in the diameter of collagen
ﬁbrils, in combination with a reduction in their synthesis, was
pointed to be the cause of impaired mechanical properties of the
skin which characterize this group of patients [110]. These exper-
imental data were veriﬁed in ﬁbroblast cell cultures (of two pa-
tients with aspartylglucosaminuria), which demonstrated a
reduction at the mRNA levels of collagen type I and III [111]. Final-
ly, taking into consideration that collagens represent molecules
abundant in the oral mucosa, collageneous elements of the ECM
were studied in several LSDs in this tissue as well. In aspartyglu-
cosaminuria, a variation in the diameter of collagen was prominent
in gingival tissue [112]. In addition, Beige mice, which represent
the analog for human Chediak-Higashi disease, were demonstrated
to have a reduction in collagen biosynthesis in oral mucosa [113].
Finally, an increase in immature collagen biosynthesis was found
in the gingival tissue from a female patient with Pompe disease
[114]. This ﬁnding may be indicative of disturbed collagen homeo-
stasis, although it was not possible to make a pathogenic correla-
tion in order to explain the gingival overgrowth of the patient.
4.2. PG expression in LSDs
Since all GAGs, with the exception of HA, are attached to protein
cores to form PGs, it is easily understood why this family of ECM
molecules has been studied in various MPS animal models, as well
as human patients. A common ﬁnding of those studies is the alter-
ations in PG arrangement, size and expression, which are universal
in almost all types of the disease and in a wide range of cells and
tissues; nevertheless, no alterations were found concerning PG
turnover in ﬁbroblast cell cultures [115]. In an effort to provide
an explanatory theory regarding skeletal features of the disease,
PG expression was studied in the articular cartilage in MPS types
characterized by bone and joint involvement. In relation to MPS
IV an alteration in the arrangement and increased amount of PGs
were demonstrated [92,93], with a parallel decrease of aggrecan
expression both at the protein and mRNA level [93]. In contrast
to the previous study using human articular cartilage, experiments
in animals have shown an up-regulation in aggrecan expression in
MPS IV chondrocytes in comparison to unaffected cells [94]. Con-
cerning MPS IX, where osteoarthritis represents a characteristic
feature of the disease, a loss in PGs was demonstrated in an animal
model with prominent signs of skeletal involvement since the age
of 3 months [77]. Knowing that PGs are ECM molecules that play a
signiﬁcant role in the developing brain, Ohmi et al. studied the
expression of glypicans in the medial entorhinal cortex of various
types of MPS mice [116]. The authors found a signiﬁcant increase
in the expression of glypican 1 and 5 in MPS IIIA and IIIB mice,
which are two disease types characterized by profound cognitive
impairment. In addition, an extralysosomal accumulation of PGs
was demonstrated, probably leading to the formation of amyloid-
beta peptide and Ptau. The latter provides direct evidence for the
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of MPS and Alzheimer’s disease [116]. Finally, numerous studies
concerning PG molecules have been conducted in order to explain
corneal opaciﬁcation which can result from abnormal GAG accu-
mulation and dysregulation of the ﬁbrillar order in this tissue. A
signiﬁcant elongation of PG ﬁlaments in addition to their various
size changed their architecture and arrangement in MPS I
[97,98], IVA [100] and VII [76], in relation to the ﬁndings of a nor-
mal cornea. Increased amounts of these molecules were also found
in the cornea of a 16-year-old patient with MPS VI [117] and in the
interphotoreceptor matrix of MPS VII affected animals [118].
PGs have been also studied in several other LSDs where the
alteration in the expression of those molecules has been proposed
to be implicated in the aetiopathogenesis of the disease. Such an
example is the identiﬁed decrease in heparan sulfate PG degrada-
tion of Niemann-Pick type C ﬁbroblasts [119]. This ﬂaw in PG
metabolism leads to the accumulation of an excess of reactive
nitrogen species, providing direct evidence of possible pathogenic
correlations with the neuro-degeneration characterizing the dis-
ease [119]. The late-infantile type of neuronal ceroid lipofuscinoses
(LINCL) represents another illustrative example of how a difference
in PG expression could potentially be involved in disease develop-
ment and progression. Teixeira et al. have shown that LINCL ﬁbro-
blasts exhibit a 48-fold increase in the expression of versican,
which is a signiﬁcant molecule in ECM of the brain [120]. This in-
creased versican expression was hypothesized to be a potential
disease causing mechanism, especially concerning the CNS
involvement of the disorder, due to possible defects in cell to cell
interactions and intracellular organization resulting from the spe-
ciﬁc PG differential expression. In aspartyglucosaminuria an alter-
ation in the epimerization of PGs [110], in combination with a
reduction in the synthesis of biglycan and an increase in the pro-
duction of decorin, were identiﬁed [111]. This differential expres-
sion of PGs was hypothesized as the possible causative
mechanism for the observed alterations in the skin collagen ﬁber
expression and arrangement [110,111]. In the same disorder, a
PG-rich ECM in gingival tissue of a patient was found [112]. Finally,
concerning LSDs with prominent skeletal involvement, an alter-
ation in PG expression was found in the cartilage of mucolipidosis
and I-cell disease patients [107,121], while a reduction in PG
expression was characteristic in chondrocytes obtained from a
GM1 gangliosidosis canine animal model [106].
All the above mentioned alterations in the expression of various
PGs could be reﬂected in the concentration of their circulating lev-
els in body ﬂuids, such as blood and cerebrospinal ﬂuid, and, thus,
these ECM components could potentially represent potential BM in
diverse LSDs.
4.3. HA expression in LSDs
Concerning HA, MPS are the kind of LSD where, this highly com-
plex in function molecule, is mainly involved. The ﬁrst relevant
description concerned a 14-year-old female patient with a deﬁ-
ciency in one hyaluronan metabolizing enzyme [122]. This patient
had a surprisingly mild phenotype with periarticular soft masses
and short stature as the main clinical features of the disorder.
Two disease causing mutations were identiﬁed in the gene which
encodes hyaluronidase 1 [123]. The patient displayed a signiﬁcant
increase in HA serum concentration [122]. In addition, a mouse
model of MPS IX was generated, where hyaluronidase 1 was com-
pletely deﬁcient, as well [77]. In this animal model hyaluronidase 3
was up-regulated, while, as opposed to the human patient, no
alteration in the circulating levels of HA was found. A few years
ago, the generation of a viable mouse model with hyaluronidase
2 deﬁciency [124], raised suspicion about the possible existence
of additional, not yet described, MPS types in humans, resultingfrom a deﬁciency in an enzyme involved in HA metabolism. This
animal model was characterized by the presence of abnormal
chondroskeletal features and was demonstrated to have a 10-fold
increase in circulating HA levels. Abnormal hyaluronan metabo-
lism was additionally found in cultured skin ﬁbroblasts from a pa-
tient suffering from MPS I [125]. These experiments, conducted
almost 40 years ago, led to the conclusion that Hurler-derived
ﬁbroblasts have an increased capacity of HA de novo production.
Concerning the expression of HA in body ﬂuids, apart from MPS
IX, there is, to the best of our knowledge, only one study in a pa-
tient with Sanﬁlippo A syndrome [126]. This patient exhibited a
5-fold increase in serum HA providing evidence for a possible
use of this macromolecule as a marker of bone involvement, while
also a reduction in hyaluronidase 1 activity was noted. In the same
study, MPS IV patients were characterized by normal hyaluroni-
dase 1 enzyme activity. In relation to other body tissues, the iden-
tiﬁcation of GAG content of multiple dentigerous cysts in one MPS
VI patient revealed an increased amount of HA, which nevertheless
was not associated with the disease, since hyaluronan represents
the main GAG in this type of cysts in general [127]. Finally, an in-
crease in hyaluronan content was found in the adenoids of an MPS
II patient [128].
Concerning other LSDs, experiments in ﬁbroblasts derived from
patients with mucolipidosis have shown contradictory results.
Bach et al., have demonstrated a 10-fold increase in the synthesis
of HA [129], while no differences have been found in hyaluronan
production by Goldin et al. [130]. This inconsistency in ﬁndings
was probably the result of different experimental procedures, since
in the ﬁrst scientiﬁc group, GAGs were determined according to
their migration using cellulose acetate electrophoresis [129], while
the second employed high-performance liquid chromatography
analysis for the direct quantiﬁcation of GAGs [130]. In relation to
the circulating levels of HA, there is only one study in a patient
with I-Cell disease who exhibited a 4-fold increase in serum HA
levels, but a normal hyaluronidase activity [126]. In the same study
a patient with GM1 gangliosidosis showed no alteration in the
activity of HA degrading enzymes, as well.
Taking into consideration that high concentrations of HA have
been demonstrated in a wide range of diseases involving organs af-
fected in LSDs [33], the need for the study of circulating hyaluro-
nan levels is imperative in this group of disorders, as well.
4.4. MMP expression in LSDs
Many members of the MMP family have been investigated in a
wide range of tissues in animal models of various MPS types, such
as in MPS I [103,104], VI [131,132] and VII [104,131–134]. A com-
mon characteristic of all these studies was the alteration in the
expression of the studied proteolytic enzymes, concerning MMP-
1 [131], MMP-3 [133], MMP-12 [103,104], MMP-13 [131], as well
as the two members of the gelatinase family, MMP-2 and MMP-9
[132,134]. Taking into consideration that MMPs are secreted as
proenzymes and require proteolytic activation in order to exert
their functions, the study of their enzyme activity represents a
promising research ﬁeld, as well. In this respect, Simonaro et al.,
have shown a prominent increase in the enzyme activity of
MMP-2 and MMP-9 in the MPS VI and MPS VII animal models
[132]. Despite the above mentioned ﬁndings, there is still scarce
data regarding the expression of MMPs in human patients with
MPS. Recently, Di Natale et al., studied the expression of MMP-9
in a small cohort of MPS VI patients [135]. The authors have found
a decrease in the expression of MMP-9 which, however, has not
reached a statistically signiﬁcant level. In addition, it was shown
that the expression of MMP-1 is decreased in human pluripotent
stem cells which were generated from skin ﬁbroblasts of MPS IIIB
children [102]. We have recently demonstrated that gelatinase
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[136]. MMP-2 was signiﬁcantly increased concerning both the en-
zyme activity and circulating levels, while a decrease in gelatino-
lytic activity and serum expression of MMP-9 was observed.
Those differences were even more pronounced in MPS III patients.
Given the fact that alterations in circulating levels of gelatinases
have been demonstrated in Alzheimer’s disease [137,138], in com-
bination with the ﬁnding that an over production of these enzymes
is coupled with an increased permeability of the blood–brain-bar-
rier [139], those ECM molecules could possibly represent BMs
demonstrating CNS involvement. In relation to treatment respon-
siveness, we have additionally demonstrated alterations in circu-
lating levels and enzyme activity of gelatinases in an MPS VI
patient under ERT, classifying these molecules as possible candi-
dates for follow-up markers [136].
Several studies for other LSDs have described alterations in
MMP expression. Among those studies, a research team has found
a disruption in the blood–brain-barrier in neuronal ceroid lipofus-
cinosis mice, due to an MMP dependent degradation of tight-junc-
tion proteins [140]. This scientiﬁc work has raised important
questions in regards to other diseases of the group, characterized
by CNS involvement, since an up-regulation in MMP expression
could be implicated in the brain pathology of other LSDs with neu-
rological features, as well. Most importantly, dietary supplementa-
tion with an antioxidant/anti-inﬂammatory polyphenol resulted in
a reduction in MMP expression and an increase in tight-junction
proteins, providing for the ﬁrst time evidence of a possibly effec-
tive therapy for the maintenance of blood–brain-barrier integrity
[140]. Dhami et al., have demonstrated an almost 10-fold increase
in the expression of MMP-12 in the lungs of an acid sphingomye-
linase-deﬁcient mouse model [10]. Pulmonary involvement is a
signiﬁcant manifestation in human patients with Niemann-Pick
disease; thus, the up-regulation of a proteolytic enzyme could
potentially represent a BM correlating to lung pathology. Shah
et al. made the ﬁrst signiﬁcant attempt to identify a BM among
the members of the MMP family in an easily accessible body ﬂuid
[141]. This research team hypothesized that an abnormal ECM
turnover could potentially characterize Fabry disease patients
and explain the cardiac manifestations of the disorder. They have
found a statistically signiﬁcant increase in MMP-9 circulating lev-
els, which correlated with the endocardial fractional shortening
observed in Fabry disease patients, providing evidence of a possible
use of this molecule as a BM for cardiac involvement. Concerning
the enzyme activity of MMPs, it was recently demonstrated that
sialidosis’ mice show an increase in their gelatinase activity [89].
This was not surprising, since this animal model was at the same
time shown to present an excessive synthesis of ECM molecules,
which represent the substrates of MMP-2 and MMP-9 [89]. Finally,
collagenase and gelatinase activity were increased in the oral
mucosa of an animal model of Chediak-Higashi disease, which pro-
vided an explanatory mechanism for the inﬂammatory periodontal
features of the disorder [142].
5. Therapeutic implications of ECM molecules in LSDs
Taking into consideration that several ECMmolecules are differ-
entially expressed in various LSDs, an important question is raised:
whether the alterations in the ECM could have an effect on current
treatment modalities used in LSDs. An illustrative example con-
cerning this matter is that of globoid cell leukodystrophy or Kra-
bbe’s disease. Patients suffering from this devastating disorder
are characterized by peripheral neuropathy which is resistant to
hematopoietic stem cell transplantation [143]. Kagitani-Shimono
et al., have recently demonstrated that the generation of ECM in
the endoneurial spaces in globoid cell leukodystrophy mice couldbe potentially the cause of persistent peripheral nerve system
dysfunction even after bone marrow transplantation [109].
Since ERT represents the treatment modality drawing great atten-
tion and offering new potential in LSD management, another
important question is raised at this point: do the ECM alterations
interfere with the cellular delivery of recombinant therapeutic
enzymes? This question represents a matter which needs further
research.
Providing proof of the possible involvement of ECM compo-
nents in the aetiopathogenesis of LSDs could orientate research to-
wards the use of those molecules as pharmaceutical targets and
may pave the way to more speciﬁc treatment modalities. It is al-
ready known that HA expression is correlated with various malig-
nant tumors, whereas HA oligomers have been used
therapeutically because of their ability to inhibit tumor growth
[43]. Furthermore, MMPs represent signiﬁcant drug targets and
various synthetic MMP inhibitors have been used in numerous
pathological conditions, such as cancer, as well as other brain, car-
diovascular, respiratory and inﬂammatory diseases [144–147].
Since LSDs are diseases affecting multiple organs, the application
of such therapeutic options could be beneﬁcial for patients suffer-
ing from this group of disorders.
Finally, apart from the possible use of the above mentioned
molecules as therapeutic regimens for LSDs, the use of ECM com-
ponents could potentially lead to the development of novel treat-
ment modalities. Sarrazin et al., have recently demonstrated that
the conjugation of a speciﬁc activated ester of guanidinylated neo-
mycin to two lysosomal enzymes enhanced the binding of these
complexes to heparan sulfate PGs [148]. Deﬁcient for the speciﬁc
enzymes cells took up signiﬁcant amounts of the conjugated forms,
resulting in the normalization of substrate accumulation and pro-
viding evidence of an efﬁcient alternative method for enzyme
delivery.
6. Conclusions
LSDs represent devastating diseases affecting multiple tissues
and organs. Recent ﬁndings regarding the extracellular accumula-
tion of diverse substrates in various disorders of the group have di-
rected research towards ECM molecules. Several studies
demonstrated signiﬁcant alterations in the expression of ECM
components, raising important questions in relation to the possible
involvement of this intricate network of macromolecules in disease
pathogenesis and providing evidence for their possible use as dis-
ease BMs; yet, a sound proof of their true value is needed before
they can be used in clinical decision making. It remains to be seen
whether new BMs for LSDs will arise from the rational application
of novel molecular techniques or the imaginative concepts of
investigators. Most importantly, scientists must always keep in
mind that body tissues are made up of both cells and surrounding
ECM and that in complex diseases, such as LSDs, these components
should ideally be studied simultaneously.
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